InventisBio

Executive Summary

InventisBio is a clinical-stage Chinese biotech focused on novel small molecule therapeutics for oncology and metabolic diseases. Its lead asset, D-1553, is a KRAS G12C inhibitor currently in global Phase 2 trials, targeting a validated oncogene with high unmet need. The company leverages a proprietary structure-based drug design platform to generate selective and potent candidates. Despite a competitive KRAS G12C landscape, D-1553's early data suggest potential for differentiation, and the company is advancing additional pipeline programs. Financially, InventisBio is publicly traded but lacks disclosed valuation; its progress depends on successful clinical execution and potential partnerships. The near-term outlook hinges on data readouts and regulatory interactions that could de-risk the pipeline and drive value inflection.

Upcoming Catalysts (preview)

• Q4 2026D-1553 Phase 2 clinical data readout55% success
• Q2 2027Initiation of pivotal trial for D-1553 in NSCLC70% success
• Q2 2027Potential partnership or licensing deal for D-1553 outside China40% success